Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Enzo and NIH File Patent Application for Autoimmune Diseases

Published: Thursday, May 09, 2013
Last Updated: Thursday, May 09, 2013
Bookmark and Share
Collaborators filed a patent application for the management of autoimmune diseases that may include age-related macular degeneration (AMD), which is a leading cause of blindness in the United States.

 The product platform is broadly applicable to the management of autoimmune disorders and includes therapeutic compositions and methods of treatment, as well as compositions and methods for diagnostic and prognostic applications.

Recent evidence indicates that AMD may be an autoimmune disease. According to the NEI, advanced AMD affects more than 2 million people in the United States, and it is estimated that almost 3.6 million will be affected by the year 2030 due to the aging population. Researchers have identified 80-100 different autoimmune diseases and suspect at least 40 additional diseases of having an autoimmune basis. The NIH estimates up to 23.5 million Americans suffer from these chronic and life-threatening diseases and that the prevalence is rising. The product platform of the patent application not only permits more accurate identification of epitopes to which a patient exhibits autoimmunity, but also allows identification of compounds that can more effectively modulate immune responses and provides therapy that is best tailored for management of the disease. Beyond that, the platform provides for cell therapy for the management of autoimmune disease.

The invention is a result of a scientific collaboration between Enzo and the NIH. Robert Nussenblatt, M.D., Chief of NEI’s Laboratory of Immunology, and two other NEI researchers are co-inventors of the application. Dr. Nussenblatt, a world-renowned ocular immunologist and expert in clinical research design and conduct, has authored or co-authored more than 400 publications and a number of books. Dr. Elazar Rabbani, Chairman of the Board of Directors and Chief Executive Officer of Enzo, and Dr. James Donegan, Enzo senior scientist, are also inventors.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Gut Microbiomes Of Infants Have An Impact On Autoimmunity
Exposure to pathogens early in life is beneficial to the education and development of the human immune system.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Vaccinations Are More Effective When Administered In The Morning
Research from the University of Birmingham shows that influenza vaccinations have more protective responses when administered in the morning.
Secrets of a Deadly Virus Family Revealed
Scripps Research scientists uncover the glycoprotein structure of LCMV. The findings could guide development of treatments for Lassa fever.
Cytokine Triggers Immune Response at Expense of Blood Renewal
Research highlights promise of Anti-IL-1 drugs to treat chronic inflammatory disease.
Reduced Immune Response Causes Flu Deaths in Older Adults
Yale study suggests that immune response to flu causes death in older people, not the virus.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!